Lexington, Mass. – April 14, 2017 - Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that it is sponsoring a webinar by Dr. Jennifer E. Van Eyk, professor of medicine, Cedars-Sinai Medical Center, on the need for precise protein quantification and identification in personalized medicine on Tuesday, April 18, 2017 from 1:00 – 2:00 p.m. EST.
- Who: Dr. Jennifer E. Van Eyk, professor of medicine, Cedars-Sinai Medical Center
- What: “Personalized Medicine: The Need for Precise Protein Quantification and Identification”
- When: Tuesday, April 18 from 1:00 – 2:00 p.m. EST
- Why: In this webinar, Dr. Van Eyk will discuss how the ability to accurately identify and quantify small changes in low abundant proteins is enabling healthcare professionals to better understand how patient heterogeneity influences disease development and treatment outcomes. The webinar will also discuss the use of Quanterix’ digital health solution, Simoa. Operating at a sensitivity up to 1,000 times greater than traditional ELISA technologies, the Simoa HD-1 Analyzer can identify these crucial biomarkers, even at trace concentrations, with extremely high precision. This is enabling the early detection of diseases across a variety of therapeutic areas, including neurology, cardiology, oncology, infection disease and inflammation.
“We’re honored to have Dr. Van Eyk share her insights and experiences with our colleagues, customers and partners,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “Her extensive work and accomplishments in the field of personalized medicine have greatly enhanced our understanding of the role protein expression profiles play in disease progression and prognosis. Having Simoa involved in her work makes us very proud, and we’re looking forward to an informative and engaging discussion.”
To register for the webinar, please visit: http://www.quanterix.com/resources/webinars/personalized-medicine-need-precise-protein-quantification-and-identification.
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.